Previous 10 | Next 10 |
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q3 2019 Earnings Call Nov 7, 2019 , 8:00 a.m. ET Operator Continue reading
Lexicon Pharmaceuticals ( LXRX +3.9% ) Q3 results : More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Livongo Health (NASDAQ: LVGO ) +22% after Q3 results . More news on: Livongo Health, Inc., DexCom, Inc., InflaRx N.V., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q3 GAAP EPS of $1.95 beats by $1.41 . Revenue of $294.4M (+4105.7% Y/Y) beats by $282.4M . Press Release More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
THE WOODLANDS, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended September 30, 2019. “We continue to make good progress on our XERMELO business, with...
THE WOODLANDS, Texas, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:0...
SAN DIEGO, CA / ACCESSWIRE / October 29, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares. Investors, who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in March 2016 or ...
THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO ® (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multi...
Gainers: Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...